Preliminary Safety, Antitumor Activity, and Circulating Tumor DNA (ctdna) Changes with RMC-9805, an Oral, RAS(ON) G12D-selective Tri-Complex Inhibitor in Patients with KRAS G12D Pancreatic Ductal Adenocarcinoma (PDAC) from a Phase 1 Study in Advanced Solid Tumors.
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined